Pipeline Value assumption at some time in the future. ART 621 $164m $219m PMX53 $ 68m $ 84m PMX-AMD $ 56m $103m ART101 $ 21m $ 27m ART104 $ 21m $ 33m ART010 $ 19m $ 27m ART150 $ 5m $ 7m ART140 $ 5m $ 8m ART160 $ 5m $ 5m Sub Total $444m Low End Sub Total $593m High end
Platforms Technology Value assumption Superhumanisation $ 20m Synhumanistaion $ 20m EvoGene $ 20m Sub Total $60m
Sub Total $22m Milestones Sub Total $220m Royalities
So a sum of parts calculation could look something like this.
Low End High End Cash $180m $180m Royalities $ 80m $ 80m Grants $ 7m $ 7m PipeLine $364m $513m Platforms $ 60m $ 60m Partnerships $242m $242m
Total $ 933m $1082m
COMPARE THE TWO
ARANA – market cap today is $ 244 Million Arana has 7 products in development 1 in the clinic. 1 in collaboration with Kyowa. Arana has 11 in Partnership deals with Milestone and royalties expected on sales. Arana has 3 technology platforms.
DOMANTIS – Sold for GBP 230 Million this equates to A$575 Million Domantis had 5 products in development None in the Clinic. 9 in partnership deals. And 1 technology platform, this I could be wrong on.
Well is Arana undervalued,, anyone.
AAH Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held